IL6pro-Luc/EF1α-mCherry Reporter Cell Line - HepG2

The HepG2 cell line, originally derived from human liver biopsy tissue, remains one of the most widely utilized models for studying hepatic metabolism, toxicology, and oncology due to its preservation of many liver-specific functions. To enhance its utility in immunological research, the IL6pro-Luc/EF1α-mCherry Reporter HepG2 cell line was developed as a sophisticated tool for monitoring inflammatory signaling. This engineered line integrates a dual-reporter system: the Firefly luciferase gene is driven by the human IL-6 promoter, providing a highly sensitive bioluminescent readout of transcriptional activation, while the mCherry fluorescent protein is constitutively expressed under the control of the EF1α promoter. This design enables researchers to quantify IL-6 induction in response to various stimuli while simultaneously using the red fluorescent signal as an internal control to normalize for cell density and viability, ensuring high data reproducibility and accuracy.

This reporter cell line is an essential resource for drug discovery and the study of cytokine-mediated signaling pathways, particularly the IL-6/STAT3 axis. It is extensively used in high-throughput screening assays to identify novel anti-inflammatory compounds and to evaluate the efficacy of therapeutic agents in a liver-specific context. Beyond drug screening, the cells are ideal for investigating the hepatotoxic effects of environmental pollutants or pathogens that induce inflammatory responses. Because the mCherry signal acts as a live-cell tracker, the line is also suitable for longitudinal studies where monitoring cell survival alongside promoter activity is critical. By offering a standardized, quantitative platform to measure cytokine promoter activity, this reporter line significantly accelerates research into chronic liver inflammation, autoimmune conditions, and the complex interplay between the immune system and hepatic function.